Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/4/2018
SIETES contiene 92257 citas

 
 
 1 a 20 de 310 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]
3. Cita con resumen
Anónimo. Eltrombopag et aplasie médullaire sévère. Prescrire 2016;36:737-9. [Ref.ID 100891]
4. Cita con resumen
Anónimo. Reacciones adversas a medicamentos registradas en el Conjunto Mínimo Básico de Datos (CMBD). Boletín de Farmacovigilancia de la Región de Murcia 2011;23:1-2. [Ref.ID 92092]
5. Cita con resumen
Han J, Lee H, Lee YS, Bae Y-J, Cho YS, Moon H-B, Kim T-B. Cephalosporin-induced recurrent aplastic anemia. Eur J Clin Pharmacol 2011;67:317-8. [Ref.ID 90102]
6. Cita con resumen
Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010;153:600-6. [Ref.ID 89833]
7. Cita con resumen
Anónimo. Acide mycophénolique: aplasies de la lignée rouge. Prescrire 2009;29:432. [Ref.ID 86021]
8. Cita con resumen
Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61. [Ref.ID 84722]
9. Cita con resumen
Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW. Evaluation of serious adverse drug reactions. A proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 2007;167:1041-9. [Ref.ID 80227]
10. Cita con resumen
Ibáñez Ruiz C, Albarracín Serra A. Farmacovigilancia en el CMBD. Boletín Informativo del Centro de Farmacovigilancia de la Comunidad de Madrid 2006;13:1-7. [Ref.ID 79466]
11.
Anónimo. Epoetin products. Labels to warn of severe anaemia and pur red cell aplasia. USA. WHO Pharmaceuticals Newsletter 2006;1:2. [Ref.ID 76315]
12. Cita con resumen
Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions - systematic literature survey of follow-up. BMJ 2006;332:335-8. [Ref.ID 76200]
13. Cita con resumen
Guerrini R. Epilepsy in children. Lancet 2006;367:499-524. [Ref.ID 76166]
14. Cita con resumen
Ballarín E, Ibáñez L, Hernández JA, Force L, Laporte JR. Cyanamide-induced aplastic anemia. Eur J Clin Pharmacol 2005;61:467-9. [Ref.ID 74857]
15. Cita con resumen
Oransky I. Sir Richard Doll. Lancet 2005;366:448. [Ref.ID 74582]
16. Cita con resumen
Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647-56. [Ref.ID 73693]
17.
Fibbe WE. Telomerase mutations in aplastic anemia. N Engl J Med 2005;352:1481-3. [Ref.ID 73342]
18. Cita con resumen
Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, Lansdorp PM, Young NS. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413-24. [Ref.ID 73337]
19.Tiene citas relacionadas Cita con resumen
Risitano A M, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR ß-CDR3 sequencing. Lancet 2004;364:355-64. [Ref.ID 70914]
20.Tiene citas relacionadas Cita con resumen
Marsh JCW, Gordon-Smith EC. Insights into the autoimmune nature of aplastic anaemia. Lancet 2004;364:308-9. [Ref.ID 70905]
Seleccionar todas
 
 1 a 20 de 310 siguiente >>